Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | HTT | P42858 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | CRHBP | P24387 | 2/20 | 0.65 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38660303 | 0.85 | TDP1 (0.75) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL38659614 | 0.85 | TDP1 (0.75) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL12869734 | 0.85 | MEN1 (0.84) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL12869852 | 0.83 | KDM4E (0.70) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL12870001 | 0.82 | TDP1 (1.00) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL12869971 | 0.80 | MEN1 (0.73) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL38660692 | 0.80 | MEN1 (0.76) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL10674767 | 0.79 | MEN1 (1.00) | KDM4EHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL38659022 | 0.79 | TDP1 (0.72) | TDP1KDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL38658863 | 0.78 | MEN1 (0.76) | TDP1KDM4EHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445677-B2 | Substituted pyrimidyl guanidine derivatives having anticancer activity | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445677-B2 | Substituted pyrimidyl guanidine derivatives having anticancer activity | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100160313-A1 | DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160313-A1 | DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160313-A1 | DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE | ABCG2, NQO2, TOP1 | TDP1 2527/4885KDM4E 1116/4885HTT 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.